Top Tweets for #DB04

over 2 years ago

@VKaklamani @dradityabardia 3. #TDxd approved for HR+ and TNBC with low Her2 on 8/5/22 based off: #DB04 - mFU 32mos, OS 23.9mos vs 17.6 mos (in Hr+, HR: 0.69) - OS 22.9mos vs 16.8mos (in All Pts, HR: 0.69) https://t.co/BSy6M2crQB #bcsm 4/6

OncBrothers's tweet photo. @VKaklamani @dradityabardia 3. #TDxd approved for HR+ and TNBC with low Her2 on 8/5/22 based off: #DB04

- mFU 32mos, OS 23.9mos vs 17.6 mos (in Hr+, HR: 0.69)
- OS 22.9mos vs 16.8mos (in All Pts, HR: 0.69)

https://t.co/BSy6M2crQB

#bcsm

4/6 https://t.co/WNZgtUbyYU

Antonio Marra @antoniomarraMD

over 3 years ago

Phenomenal data in 2022, but 1 study that has resulted in a paradigm shift in how we treat/label #breastcancer #DB04 by #ShanuModi from @MSKCancerCenter Full Intv: - https://t.co/UxeB1tqZWD - Also on “Oncology Brothers” podcast #OncJrnlClub #MedTwitter #OncEd @ASCO #bcsm

1

26

3

9K

1

9

1

0

1K

Lurraldebus @Lurraldebus

over 2 years ago

📅 Urriak 25 / 25 de octubre 📢 Gutxieneko zerbitzuak / Servicios mínimos ⭕ Greba - lanuzteak @euskotren / Huelga - jornada de paros #Euskotren 🚌 #DB01 #DB02 #DB03 #DB04 #DB05 #DB06 #UK07 #UK08 #UK09 #UK10 #UK11 📱 900 300 340 🔗https://t.co/79USwgHemj

Lurraldebus's tweet photo. 📅 Urriak 25 / 25 de octubre

📢 Gutxieneko zerbitzuak / Servicios mínimos

⭕ Greba - lanuzteak @euskotren / Huelga - jornada de paros #Euskotren

🚌 #DB01 #DB02 #DB03 #DB04 #DB05 #DB06 #UK07 #UK08 #UK09 #UK10 #UK11

📱 900 300 340

🔗https://t.co/79USwgHemj https://t.co/t6jpLXuMWg

0

4

5

0

2K

over 2 years ago

Insightful discussion by @BianchiniGP on the practical implications of #DB04 results and challenges in sequencing emerging ADCs @myESMO #ESMO23

antoniomarraMD's tweet photo. Insightful discussion by @BianchiniGP on the practical implications of #DB04 results and challenges in sequencing emerging ADCs @myESMO #ESMO23 https://t.co/DOMpsb85Ru

0

8

3

0

814

Antonio Marra @antoniomarraMD

over 2 years ago · Madrid

Very important updated analysis of the #DB04 presented by Shanu Modi showing long-term benefit for T-DXd over chemo in advanced breast cancer @MSKCancerCenter @myESMO #ESMO23

Erika Hamilton, MD, FASCO @ErikaHamilton9

over 2 years ago

Dr. Modi presents updated #DB04 results with #TDXd in #HER2low ▫️Median f/u 32.0 mo ▫️ OS HR 0.69, 17.6 to 23.9 mo for HR+, ▫️PFS HR 0.36 , 4.2 to 9.6 mo for HR+, ▫️TNBC OS 8.3 to 17.1 mo, PFS 2.9 to 6.3 mo...smaller # though #ESMO23 #bcsm

ErikaHamilton9's tweet photo. Dr. Modi presents updated #DB04 results with #TDXd in #HER2low

▫️Median f/u 32.0 mo

▫️ OS HR 0.69, 17.6 to 23.9 mo for HR+,

▫️PFS HR 0.36 , 4.2 to 9.6 mo for HR+,

▫️TNBC OS 8.3 to 17.1 mo, PFS 2.9 to 6.3 mo...smaller # though

#ESMO23 #bcsm https://t.co/UDaRJFXQ4J

0

30

9

4

8K

0

8

2

1

966

Erika Hamilton, MD, FASCO @ErikaHamilton9

over 2 years ago

#ESMO23 S.Modi presents the updated results from #DB04 (f-up 32 months), confirming a major benefit in PFS and OS with T-DXd (vs chemo) in patients with HER2-low mBC. 15% of pts receiving T-DXd were free from progression at 2y (vs 0% with chemo). Impressive. #bcsm

PTarantinoMD's tweet photo. #ESMO23 S.Modi presents the updated results from #DB04 (f-up 32 months), confirming a major benefit in PFS and OS with T-DXd (vs chemo) in patients with HER2-low mBC. 15% of pts receiving T-DXd were free from progression at 2y (vs 0% with chemo). Impressive. #bcsm https://t.co/BQr7qEaaS7

1

85

24

8

5K

over 2 years ago

Dr. Modi presents updated #DB04 results with #TDXd in #HER2low ▫️Median f/u 32.0 mo ▫️ OS HR 0.69, 17.6 to 23.9 mo for HR+, ▫️PFS HR 0.36 , 4.2 to 9.6 mo for HR+, ▫️TNBC OS 8.3 to 17.1 mo, PFS 2.9 to 6.3 mo...smaller # though #ESMO23 #bcsm

0

30

9

4

8K

Oncologia Brasil @BrasilOncologia

about 3 years ago

Dr. Carlos dos Anjos junta-se à Dra. Debora Gagliato para discutir os resultados do estudo DESTINY-Breast04. Confira todos os detalhes desta descoberta no link: https://t.co/JaZEYb6zxc #mdhealth #oncologiabrasil #ASCO2023 #DB04 #TDXd

0

25

4

0

29K

over 3 years ago

Distinguishing HER2 scores 1+ from 0 in the pre-#DB04 era

Balazs Halmos

@BalazsHalmosMD

over 3 years ago · Ridgefield

@VivekSubbiah @marklewismd @StephenVLiu @neerajaiims @mcquadeMDLAc @DrSGraff @DrChoueiri @GlopesMd @ADesaiMD @jacobadashek Getting non-contrast brain CT/MR to rule out brain mets😉👇

0

31

3

0

11K

2

46

4

9K

over 3 years ago

Phenomenal data in 2022, but 1 study that has resulted in a paradigm shift in how we treat/label #breastcancer #DB04 by #ShanuModi from @MSKCancerCenter Full Intv: - https://t.co/UxeB1tqZWD - Also on “Oncology Brothers” podcast #OncJrnlClub #MedTwitter #OncEd @ASCO #bcsm

1

26

3

9K

over 3 years ago

What treatments did patients receive before and after enrollment in #DB04? Detailed pre/post-trial therapies are just released in a @NEJM letter. https://t.co/jMtnss85zr

PTarantinoMD's tweet photo. What treatments did patients receive before and after enrollment in #DB04? Detailed pre/post-trial therapies are just released in a @NEJM letter.
https://t.co/jMtnss85zr https://t.co/sX3xAEXCs9

0

42

9

5

0

almost 4 years ago

Controversial poll on recent breast cancer advancements. Data from 58 #DB04 patients led to the FDA/NCCN/ASCO endorsement of T-DXd for TNBC. #MAINTAIN had double the pts (n=120) and showed the benefit of CDK4/6-inh beyond PD. Are we ready to adopt CDK4/6-inhibition beyond PD?

5

12

3

4

0

Erika Hamilton, MD, FASCO @ErikaHamilton9

almost 4 years ago

#TDxD is now @FDAOncology approved for low HER2 mBC. Our discussion with @stolaney1 post @ASCO on #DB04 that led to this approval: - HR+ve mPFS 10mos Vs. 5.4mos (HR: 0.51) - mOS 24mos Vs. 17.5mos #BCSM #OncTwitter @DaiichiSankyoUS @OncoAlert @HemOncFellows @DFCI_BreastOnc

0

50

21

8

0

almost 4 years ago

#DB04 out in print now, #TDXd for #HER2low #bcsm. Actionable across traditional #TNBC and #HR+ phenotypes. Congrats Dr. Modi, ⁦@prat_aleix⁩, ⁦@hoperugo⁩, etc. Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Br Ca | NEJM https://t.co/A55NjL6qE6

0

55

21

5

0